Novacyt Confident Of Further APAC Growth
Executive Summary
Clinical diagnostics firm Novacyt is confident of further growth in Asia-Pacific after sales in China exceeded the company's expectations.
You may also be interested in...
Novacyt Lands New US Supply Deal, Maps Path To Profitability
Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns.
Novacyt Raises €9.7M, Ahead Of UK IPO
Clinical diagnostics firm Novacyt has raised €9.7M from UK and French investors ahead of plans to dual list on the London Stock Exchange Alternative Investment Market (AIM). The Cambridge, UK-based company is currently listed on the Euronext Growth Paris exchange.
Novacyt Full Of Eastern Promise, Following Strong H1 Sales
Cervical cancer screening firm Novacyt is aiming to broaden its market penetration in Asia-Pacific by identifying strategic acquisitions. The Anglo-French firm posted strong sales growth of 40% for the first six months of 2017, with APAC representing the group's fastest growing region.